Peter D. Senter

20.1k total citations · 10 hit papers
179 papers, 15.2k citations indexed

About

Peter D. Senter is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Peter D. Senter has authored 179 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Radiology, Nuclear Medicine and Imaging, 102 papers in Oncology and 76 papers in Molecular Biology. Recurrent topics in Peter D. Senter's work include Monoclonal and Polyclonal Antibodies Research (112 papers), HER2/EGFR in Cancer Research (79 papers) and Glycosylation and Glycoproteins Research (24 papers). Peter D. Senter is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (112 papers), HER2/EGFR in Cancer Research (79 papers) and Glycosylation and Glycoproteins Research (24 papers). Peter D. Senter collaborates with scholars based in United States, Germany and Japan. Peter D. Senter's co-authors include Eric L. Sievers, Anna M. Wu, Stephen C. Alley, Damon L. Meyer, Nicole M. Okeley, Charles G. Cerveny, Svetlana O. Doronina, Alan F. Wahl, Brian E. Toki and Joseph A. Francisco and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Peter D. Senter

172 papers receiving 14.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

2004 909 citations Kevin J. Hamblett, Peter D. Senter et al. Clinical Cancer Research profile →
Development of potent monoclonal antibody auristatin conjugates for cancer therapy

2003 903 citations Svetlana O. Doronina, Brian E. Toki et al. Nature Biotechnology profile →
Arming antibodies: prospects and challenges for immunoconjugates

2005 825 citations Anna M. Wu, Peter D. Senter Nature Biotechnology profile →
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

2003 668 citations Joseph A. Francisco, Charles G. Cerveny et al. profile →
Antibody-Drug Conjugates in Cancer Therapy

2012 596 citations Eric L. Sievers, Peter D. Senter profile →
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

2012 577 citations Peter D. Senter, Eric L. Sievers Nature Biotechnology profile →
Antibody–drug conjugates: targeted drug delivery for cancer

2010 513 citations Stephen C. Alley, Nicole M. Okeley et al. profile →
Antibody–drug conjugates come of age in oncology

2023 460 citations Peter D. Senter et al. profile →
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

2015 390 citations Robert P. Lyon, Tim D. Bovee et al. Nature Biotechnology profile →
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

2014 358 citations Robert P. Lyon, Jocelyn R. Setter et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter D. Senter United States	58	8.2k	7.8k	6.6k	2.0k	2.0k	179	15.2k
Dario Neri Switzerland	83	10.0k 1.2×	7.4k 0.9×	15.2k 2.3×	5.0k 2.4×	3.8k 1.9×	532	25.3k
Mark X. Sliwkowski United States	52	9.8k 1.2×	14.5k 1.9×	9.9k 1.5×	1.8k 0.9×	1.1k 0.6×	111	21.9k
Vladimir Tolmachev Sweden	56	9.4k 1.1×	4.9k 0.6×	4.0k 0.6×	668 0.3×	559 0.3×	401	11.9k
John M. Lambert United States	45	3.9k 0.5×	4.0k 0.5×	3.4k 0.5×	1.8k 0.9×	567 0.3×	129	8.2k
Ralph A. Reisfeld United States	63	3.2k 0.4×	5.2k 0.7×	8.0k 1.2×	5.6k 2.8×	412 0.2×	219	16.7k
Janice M. Reichert United States	43	5.1k 0.6×	2.4k 0.3×	5.5k 0.8×	2.4k 1.2×	469 0.2×	94	9.7k
David Colcher United States	55	6.7k 0.8×	3.2k 0.4×	3.9k 0.6×	1.9k 0.9×	347 0.2×	208	9.9k
Alain Beck France	59	7.1k 0.9×	3.0k 0.4×	8.4k 1.3×	2.0k 1.0×	647 0.3×	211	12.8k
K. Dane Wittrup United States	69	8.2k 1.0×	4.0k 0.5×	10.4k 1.6×	4.4k 2.2×	380 0.2×	235	16.8k
Anthony W. Tolcher United States	62	1.7k 0.2×	7.2k 0.9×	8.8k 1.3×	2.0k 1.0×	520 0.3×	438	16.5k

Countries citing papers authored by Peter D. Senter

Since Specialization

Citations

This map shows the geographic impact of Peter D. Senter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter D. Senter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter D. Senter more than expected).

Fields of papers citing papers by Peter D. Senter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter D. Senter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter D. Senter. The network helps show where Peter D. Senter may publish in the future.

Co-authorship network of co-authors of Peter D. Senter

This figure shows the co-authorship network connecting the top 25 collaborators of Peter D. Senter. A scholar is included among the top collaborators of Peter D. Senter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter D. Senter. Peter D. Senter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roy, Debashish, Selvi Srinivasan, Vladimir A. Vlaskin, et al.. (2024). Liver-targeted polymeric prodrugs delivered subcutaneously improve tafenoquine therapeutic window for malaria radical cure. Science Advances. 10(16). eadk4492–eadk4492. 3 indexed citations

Moquist, Philip N., Xinqun Zhang, Chris Leiske, et al.. (2024). Reversible Chemical Modification of Antibody Effector Function Mitigates Unwanted Systemic Immune Activation. Bioconjugate Chemistry. 35(6). 855–866. 2 indexed citations

Disis, Mary L., Ekram Gad, Denise L. Cecil, et al.. (2020). Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers. Molecular Cancer Therapeutics. 19(5). 1102–1109. 15 indexed citations

Moquist, Philip N., Tim D. Bovee, Andrew B. Waight, et al.. (2020). Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models. Molecular Cancer Therapeutics. 20(2). 320–328. 19 indexed citations

Neumann, Christopher S., Martha E. Anderson, Julia H. Cochran, et al.. (2018). Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 17(12). 2633–2642. 32 indexed citations

Burke, Patrick, Holden W. H. Lai, Kim K. Emmerton, et al.. (2018). Glucuronide-Linked Antibody–Tubulysin Conjugates Display Activity in MDR+ and Heterogeneous Tumor Models. Molecular Cancer Therapeutics. 17(8). 1752–1760. 15 indexed citations

Burke, Patrick, Jocelyn R. Setter, Joshua H. Hunter, et al.. (2016). Development of Novel Quaternary Ammonium Linkers for Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 15(5). 938–945. 45 indexed citations

Burke, Patrick, Scott C. Jeffrey, Joshua H. Hunter, et al.. (2016). Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 16(1). 116–123. 110 indexed citations

Belcher, John D., Chunsheng Chen, Julia Nguyen, et al.. (2015). The Fucosylation Inhibitor, 2-Fluorofucose, Inhibits Vaso-Occlusion, Leukocyte-Endothelium Interactions and NF-ĸB Activation in Transgenic Sickle Mice. PLoS ONE. 10(2). e0117772–e0117772. 28 indexed citations

10.

Senter, Peter D. & Eric L. Sievers. (2012). The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotechnology. 30(7). 631–637. 577 indexed citations breakdown →

11.

Okeley, Nicole M., Jamie B. Miyamoto, Xinqun Zhang, et al.. (2010). Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research. 16(3). 888–897. 291 indexed citations

12.

Burke, Patrick, Brian E. Toki, David W. Meyer, et al.. (2009). Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. Bioorganic & Medicinal Chemistry Letters. 19(10). 2650–2653. 20 indexed citations

13.

Leipold, Douglas D., Nelson L. ‘Shasha’ Jumbe, Debra L. Dugger, et al.. (2007). Trastuzumab-MC-vc-PAB-MMAF: The effects of the Drug:Antibody Ratio (DAR) on efficacy, toxicity and pharmacokinetics.. Cancer Research. 67. 1551–1551. 3 indexed citations

14.

Alley, Stephen C., Nicole M. Okeley, Russell J. Sanderson, et al.. (2006). Intracellular metabolism of antibody-drug conjugates: identification and quantitation of released drugs. Cancer Research. 66. 469–469. 3 indexed citations

15.

Wu, Anna M. & Peter D. Senter. (2005). Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology. 23(9). 1137–1146. 825 indexed citations breakdown →

16.

Pastuskovas, Cinthia V., et al.. (2005). Tissue distribution, metabolism, and excretion of the antibody-drug conjugate Herceptin-monomethyl auristatin E in rats. Cancer Research. 65. 1195–1196. 5 indexed citations

17.

Senter, Peter D., Brian A. Mendelsohn, Brian E. Toki, et al.. (2004). Immunoconjugates comprised of drugs with impaired cellular permeability: A new approach to targeted therapy. Cancer Research. 64. 144–144. 2 indexed citations

18.

Hamblett, Kevin J., Damon L. Meyer, Dana F. Chace, et al.. (2004). Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate. Cancer Research. 64. 144–144.

19.

Bignami, Gary S., et al.. (1992). N-(4'-hydroxyphenylacetyl)palytoxin: a palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate.. PubMed. 52(20). 5759–64. 35 indexed citations

20.

Zavarin, Eugene, Karel Snajberk, & Peter D. Senter. (1979). Analysis of Terpenoids from Seedcoats as a Means of Identifying Seed Origin. Forest Science. 25(1). 20–24. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact